Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Autoantibodies against coagulation factor VIII]

L J Friis-Hansen1, N S Andersen, E Scheibel

  • 1H:S Rigshospitalet, klinisk biokemisk afdeling.

Ugeskrift for Laeger
|November 4, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authors' reply.

Scandinavian journal of rheumatology·2017
Same author

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2017
Same author

Prognostic factors associated with mortality in patients with septic arthritis: a descriptive cohort study.

Scandinavian journal of rheumatology·2016
Same author

Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.

Journal of clinical pharmacy and therapeutics·2015
Same author

Von Willebrand disease in Denmark: demography and treatment.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Immunoglobulin class-switch recombination occurs in mantle cell lymphomas.

The Journal of pathology·2006

Autoantibodies to coagulation factor VIII cause rare bleeding disorders. Early screening with specific blood tests can detect at-risk patients for timely treatment and suppression of autoantibodies.

Area of Science:

  • Hematology
  • Immunology
  • Rare Diseases

Context:

  • Autoantibodies against coagulation factor VIII (FVIII) represent a rare but serious bleeding disorder.
  • Incidence is estimated at 1-2.5 to 5 million individuals per year.
  • Clinical manifestations typically include subcutaneous or intramuscular hemorrhages and uncontrollable bleeding after minor trauma.

Purpose:

  • To outline the diagnostic criteria for autoantibodies against FVIII.
  • To describe current management strategies for bleeding and autoantibody production.
  • To recommend screening protocols for early detection of at-risk individuals.

Summary:

  • Diagnostic screening involves activated partial thromboplastin time (aPTT), prothrombin time (PT), and platelet count, often revealing a prolonged aPTT.

Related Experiment Videos

  • Treatment involves immunosuppression with prednisolone, potentially combined with chemotherapy (e.g., azathioprine), and hemostatic control using FVIII bypass concentrates.
  • Early diagnosis improves the prognosis for controlling bleeding and suppressing autoantibody formation.

    • Impact:

    • Implementing recommended screening protocols can lead to earlier identification of patients with FVIII autoantibodies.
    • Timely intervention can significantly reduce morbidity and mortality associated with this rare bleeding disorder.
    • Referral of patients with isolated prolonged aPTT to specialized coagulation laboratories is crucial for accurate diagnosis and management.